151 related articles for article (PubMed ID: 18268484)
1. Pulse pressure and dual angiotensin blockade.
Safar ME
Am J Hypertens; 2008 Feb; 21(2):133. PubMed ID: 18268484
[No Abstract] [Full Text] [Related]
2. More is less? Optimal combination therapy for adequate blood pressure lowering in hypertension.
Kjeldsen SE; Hedner T; Narkiewicz K; Oparil S
Blood Press; 2008; 17(3):132-3. PubMed ID: 18665471
[No Abstract] [Full Text] [Related]
3. Benefits and risks of combination therapy in hypertension.
Node K
Hypertens Res; 2009 Sep; 32(9):727-8. PubMed ID: 19609269
[No Abstract] [Full Text] [Related]
4. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
[TBL] [Abstract][Full Text] [Related]
5. Dual renin-angiotensin system blockade: on the target.
Robles NR
Int J Clin Pract; 2008 Aug; 62(8):1134-6. PubMed ID: 18705817
[No Abstract] [Full Text] [Related]
6. How should renin-angiotensin system blockade be applied in chronic kidney disease for optimal renal protection?
Zhang X; Hou FF
Chin Med J (Engl); 2007 Feb; 120(3):243-5. PubMed ID: 17355830
[No Abstract] [Full Text] [Related]
7. Is there added value to adding ARB to ACE inhibitors in the management of CKD?
Cohen DL; Townsend RR
J Am Soc Nephrol; 2009 Aug; 20(8):1666-8. PubMed ID: 18776118
[TBL] [Abstract][Full Text] [Related]
8. Beneficial effects of combination therapy with angiotensin II receptor blocker and angiotensin-converting enzyme inhibitor on vascular endothelial function.
Morimoto S; Maki K; Aota Y; Sakuma T; Iwasaka T
Hypertens Res; 2008 Aug; 31(8):1603-10. PubMed ID: 18971536
[TBL] [Abstract][Full Text] [Related]
9. Aldosterone antagonist therapy in resistant hypertension.
Zannad F
J Hypertens; 2007 Apr; 25(4):747-50. PubMed ID: 17351364
[No Abstract] [Full Text] [Related]
10. Defining the role of renin/angiotensin-targeted antihypertensive therapy in decreasing cardiovascular risk: evidence, guideline evolution, and questions to be resolved.
Probstfield J
J Fam Pract; 2009 Jun; 58(6 Suppl):S1-8. PubMed ID: 19508849
[No Abstract] [Full Text] [Related]
11. Effects of calcium channel and renin-angiotensin system blockade on intravascular and neurohormonal mechanisms of hypertensive vascular disease.
Mizuno Y; Jacob RF; Mason RP
Am J Hypertens; 2008 Oct; 21(10):1076-85. PubMed ID: 18756260
[TBL] [Abstract][Full Text] [Related]
12. Going after angiotensin. An ACE inhibitor or an ARB, not both, best protects the heart.
Harv Heart Lett; 2008 Jul; 18(11):2. PubMed ID: 18693363
[No Abstract] [Full Text] [Related]
13. Dual blockade of renin-angiotensin system in primary focal segmental glomerulosclerosis.
Singh A
Nephrol Dial Transplant; 2006 Mar; 21(3):830-1. PubMed ID: 16278255
[No Abstract] [Full Text] [Related]
14. Preventing complications in diabetic patients: blood pressure control essential.
Golden W; Kinggard T; Potts SG
J Ark Med Soc; 2006 Sep; 103(3):58-9. PubMed ID: 16986761
[No Abstract] [Full Text] [Related]
15. [Pharmacological hypertension therapy].
Pedersen OL; Christensen KL; Bang LE; Ibsen H; Schultz-Larsen P
Ugeskr Laeger; 2009 Jun; 171(24):2022-5. PubMed ID: 19523367
[TBL] [Abstract][Full Text] [Related]
16. [High risk arterial hypertension: the role of angiotensin II receptor blockers].
Fomin VV; Moiseev SV; Mukhin NA
Ter Arkh; 2007; 79(10):86-91. PubMed ID: 18154154
[No Abstract] [Full Text] [Related]
17. [Blood pressure control in Europe is worse than in the USA].
Minutolo R
G Ital Nefrol; 2007; 24(4):284. PubMed ID: 17659496
[No Abstract] [Full Text] [Related]
18. Stage IV chronic kidney disease.
Hirsch S
N Engl J Med; 2010 May; 362(20):1942-3; author reply 1943. PubMed ID: 20496469
[No Abstract] [Full Text] [Related]
19. Endocrine arterial hypertension: therapeutic approach in clinical practice.
Mazza A; Armigliato M; Zamboni S; Rempelou P; Rubello D; Pessina AC; Casiglia E
Minerva Endocrinol; 2008 Dec; 33(4):297-312. PubMed ID: 18923367
[TBL] [Abstract][Full Text] [Related]
20. [Marketing makes pressure! ACE inhibitors or AT2? We must choose...].
Jolidon RM
Rev Med Suisse; 2006 Oct; 2(83):2372-3; author reply 2373. PubMed ID: 17112090
[No Abstract] [Full Text] [Related]
[Next] [New Search]
